GH Earnings Prediction
The chart below shows how GH performed 10 days before and after its earnings report, based on data from the past quarters. Typically, GH sees a +1.34% change in stock price 10 days leading up to the earnings, and a -2.27% change 10 days following the report. On the earnings day itself, the stock moves by -1.46%. This data can give you a slight idea of what to expect for the next quarter's release.
GH Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
191.48M
33.87%
8.04%
Gross Margin
61.10%
2.31%
3.31%
Operating Margin
-61.28%
-22.80%
7.94%
Net Margin
-56.28%
-6.51%
-2.81%
EPS
-0.88
-20.55%
4.76%
No Data Available
GH Earnings Analysis
Guardant Health, Inc. Common Stock Corporation (GH.O) Earnings Conference Call
Positive
Record Revenue Growth: Total revenue grew 34% to a record $191.5 million, driven by a 35% increase in oncology revenue to $180.6 million.
Clinical Test Volume Growth: Clinical test volume for the third quarter grew 21% year-over-year, reaching 53,100 tests, supported by strong growth across the portfolio.
ASP Achievement Milestone: Guardant 360 ASP reached $3,000 in Q3 2024, achieving the long-term goal set for 2028 four years ahead of target.
Clinical Test Revenue Surge: Guardant 360 revenue from clinical tests totaled $39.4 million, increasing 34% year-over-year, fueled by a record number of tests performed in the third quarter of 10,500, up 40%.
Cash Flow Breakeven Outlook: The company ended Q3 2024 with approximately $1 billion in cash, sufficient to achieve cash flow breakeven by 2028.
Negative
Revenue Surge in Oncology: Total revenue grew 34% to $191.5 million, primarily driven by precision oncology revenue, which increased 35% to $180.6 million.
Adjusted EBITDA Loss Decrease: Adjusted EBITDA loss was $56.2 million in Q3 2024, a decrease of $23.5 million from Q3 2023.
Free Cash Flow Improvement: Free cash flow for the third quarter of 2024 was negative $55.3 million, an improvement of $24.9 million from $80.2 million in Q3 2023.
Operating Expenses Increase: Non-GAAP operating expenses were $187.3 million, an increase of $10 million compared to the prior quarter.
Clinical Volume Increase: Clinical volume growth of 21% was in line with our expectations and was primarily driven by Guardant 360.
GH FAQs
How does GH typically perform around its earnings report dates?
Is Guardant Health, Inc. (GH) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
GH Earning Call Sentiment
Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
GH.O
4.33%Positive
Basic Financial Performance: 4 (strong revenue growth and improved cash flow), Product Development and Business Update: 3 (positive Shield adoption but early market penetration), Market Strategy: 3 (commitment to investment with financial discipline), Expenses and Financial Health: 3 (negative cash flow but improved), Shareholder Return Plan: 2 (no buyback or dividend). Q&A revealed cautious optimism but highlighted uncertainties about Shield's market penetration and financial stability. Considering the market cap, the stock price is likely to remain stable, resulting in a neutral sentiment.
